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Abstract 
Introduction: Septic shock is a common condition encountered in the intensive care unit. Sepsis is the leading cause of death with 
mortality ranging from 35-50%. Several factors are involved in the increasing incidence of sepsis including age, immunosuppression 
and antibiotic resistance. Gram+ or Gram- infections are considered leading causes of sepsis. Septic shock prognosis is significantly 
affected by early treatment. The hospitalization of the patient in the intensive care unit is particularly important as it is essential to sup-
port vital functions due to the complications of the shock. 
Aim: To investigate the action of ascorbic acid in the treatment of septic shock and the benefits of its administration.   
Method-Material: Randomized trials were searched in CENTRAL, EMBASE and PubMed databases. The total number of studies includ-
ed was 6. The Cochrane Risk of Bias Tool Review Manager Revman 5.3 was used to control the studies. Τhe criteria for the inclusion of 
patients were: age more specifically over 18 years old, patients accepted to intensive care unit with septic shock, patients with septic 
shock who received ascorbic acid randomized studies and cohort studies and articles in English with a time limit from 2008 to the first 
semester of 2020. 
Results:  The results of the studies showed that patients with septicemia and septic shock have shown beneficial effects of ascorbic acid 
alone or in combination with corticosteroids and thiamine in the prevention of progressive organ dysfunction and in the reduction in 
mortality and severity of severe sepsis. Also, there was a reduced inflammatory response observed in septic shock and attenuated levels 
of circulatory injury biomarker. 
Conclusions: Ascorbic acid has beneficial properties in septic shock and various studies have highlighted the importance of the combi-
nation of ascorbic acid and other vitamins and trace elements. 
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Septic shock is a common condition encountered in the inten-
sive care unit. Sepsis is the leading cause of death with mortali-
ty ranging from 35-50%. Several factors are involved in the 
increasing incidence of sepsis including age, immunosuppres-
sion and antibiotic resistance. Gram+ or Gram- infection are 
considered leading causes of sepsis. Septic shock prognosis is 
significantly affected by early treatment. The hospitalization of 
the patient in the intensive care unit is particularly important as 
it is essential to support vital functions due to the complica-
tions of the shock. It is known that gram + and gram - micro-
organisms can cause the onset of septic shock syndrome. The 
endotoxin secreted by the cell wall of gram-microbes, is re-
sponsible for mobilizing the cataract of sepsis. The severity of 
the induced septic shock is proportional to the level of endo-
toxin in the patient's blood. In septic shock from gram + mi-
croorganisms is blamed more than one substance eg exotoxin 
peptidoglycans and their relationship with the severity of 
symptoms is not analogous. Regardless of the responsible sub-
stance, the response of the organism is similar, is the same 
quality disorders are observed but there are differences in the 
size of each. Sepsis is the body's systematic response to severe 
infection and is characterized by a multitude of clinical, hemo-
dynamic, hematological, immunological and biochemical 
symptoms. These are the body's effort to deal with the micro-
bial invasion. Although sepsis is triggered by a microbial infec-
tion, the cataract of various mediators is secreted, many times 
it can continue even if the microbial agent has been controlled. 
The mediators modify the reaction of certain receptors in the 
various organic systems, which in turn respond with organic or 
other secretions. Thus, they feed back this reaction creating a 
vicious circle. What causes death due to sepsis is not so much 
microgranulation as the body's reaction to it, a reaction that 
ultimately affects the functioning of all organic systems. The 
best treatment for sepsis and septic shock is prevention, and if 
this is not possible, timely and correct therapeutic intervention 
can modify the body's response to sepsis for the benefit of the 
patient. Supporting vital functions and choosing the right 
treatment should be done without delay, even on suspicion of 
sepsis.1 
Septic shock syndrome has been known since antiquity. It is a 
severe disease since it occurs in the community and in hospi-
talized patients and exhibits a high mortality rate (30-45%). The 
scientific community has published international guidelines, 
such as the "Surviving Sepsis Campaign" in 2012 that aim to 
aid the proper diagnostic and therapeutic treatment of patients 
with sepsis.2 It is important to stabilize the patient on the basis 
of specific guidelines and to administer appropriate medication 
(mainly antimicrobial) in a timely manner. Compliance with 
these guidelines has significantly reduced the mortality rate of 
sepsis patients in recent years.3 
William Osler (1849-1919) was the first to identify the role of 
the host's immune response in sepsis. He has stated the fol-
lowing: "With the exception of some cases, patients die be-
cause of their body's response to infection and not because of 
infection." This discovery was a milestone in understanding the 
role of the host's immune response to an infection.4  
In recent years, several research groups have focused on iden-
tifying compounds that can contribute to the treatment of sep-
tic shock. One of these compounds is ascorbic acid. 
 
AIM 
The aim of the present study was to assess the role of ascorbic 




A bibliographical review was carried out in the CENTRAL, EM-
BASE, PubMed databases with language restriction. The selec-
tion included articles in English with a time limit from 2008 to 
the first semester of 2020. The selection was limited to the type 
of studies (use of randomized and Cohort studies). The total 
number of studies included using the Preferred Reporting 
Items of Systemic Reviews and Meta-analysis tool was 6. The 
Review Manager – RevMan 5.3 risk of Bias Tool was used to 
assess these studies.  
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The keywords that were used to search for the studies were the 
following: Septic shock AND ascorbic acid, OR sepsis AND 
ascorbic acid, OR ascorbic acid AND shock. 
Inclusion criteria 
Τhe criteria for the inclusion  of patients were: age more specif-
ically over 18 years old, patients accepted to intensive care unit 
with septic shock, patients with septic shock who received 
ascorbic acid randomized studies and cohort studies and arti-
cles in English with a time limit from 2008 to the first semester 
of 2020. 
Exclusion criteria 
The exclusion criteria were: patient under 18 years, studies that 
were in a language other than English, studies prior to 2008, 
small number of participants and the dose of ascorbic acid or 
the description of the control group was not reported. 
The flow diagram 1 depicts the flow of information through the 
different phases of a systematic review. It maps out the num-
ber of records identified, included and excluded, and the rea-
sons of exclusion. 
 
RESULTS 
Vitamin C is considered particularly important, as L-ascorbic 
acid plays a major role in the health of animal organisms. The 
human body cannot synthesize vitamin C due to the absence 
of an enzyme. The lack of vitamin C is known to cause scurvy, a 
disease that primarily manifests itself in bleeding. To date, it 
has been shown that the adjustment of the diet and the inclu-
sion of fruits and vegetables can reduce the incidence of the 
disease. It has been also reported that the administration of L-
ascorbic acid is beneficial in patients with septic shock and 
sepsis.5 
In particular, in their research Carr et al studied a sample of 44 
patients with critical disease, of which 24 had septic shock, 17 
had no sepsis, while 3 had not been classified. The data indi-
cated that 40% of patients with septic shock developed vitamin 
C deficiency compared to 25% of non-septic patients. The 
baseline vitamin C status was 17.8 ± 8.7 μmol/L; of these, 68% 
were classified as hypovitaminosis C (i.e., < 23 μmol/L), and 
32% were deficient in vitamin C (i.e., < 11 μmol/L). Concentra-
tions of plasma vitamin C were significantly lower in septic 
shock patients than in the nonseptic patients (P = 0.03). Of the 
septic shock patients, 88% were in the hypovitaminosis C cate-
gory, compared with 50% in the non-septic patients, and 38% 
of the septic shock patients were deficient in vitamin C, com-
pared with 25% of the non-septic patients. Concluded that this 
was likely to occur due to an increase in metabolism as a result 
of the increased inflammatory response observed in septic 
shock.6 
In their study, Fowler et al.,7  randomized 24 patients with se-
vere sepsis into three groups, at a ratio of 1:1:1. The first group 
received intravenous infusions of ascorbic acid every six hours 
for four days: (Lo-Asca, 50 mg/kg/24 hn=8), the second Hi-
Asca 200 mg/kg/24 h (n=8) and the third group placebo 5% 
dextrose/water (n=8). Patients treated with ascorbic acid expe-
rienced immediate reductions in the SOFA score, while patients 
treated with placebo did not show such a decrease. Ascorbic 
acid significantly reduced the levels of the pro-inflammatory 
biomarkers C-reactive protein and procalcitonin. Unlike pa-
tients treated with placebo, thrombomodulin infusion into pa-
tients receiving ascorbic acid did not cause a significant in-
crease in induction of inflammation, indicating a weakening of 
vascular endothelial damage. 
In a previous study, Marik et al.,8  treated 94 patients in the 
ascorbic acid therapy group (n=47) (intravenous vitamin C (1.5 
g every 6 h for 4 days or until ICU discharge), hydrocortisone 
(50 mg every 6 h for 7 days or until ICU discharge followed by 
a taper over 3 days), as well as intravenous thiamine (200 mg 
every 12 h for 4 days or until ICU discharge). The vitamin C was 
administered as an infusion over 30 to 60 Intravenous thiamine 
was given as a piggyback in 50 mL of either D5W or normal 
saline and was administered as a 30-min infusion and mixed in 
a 100- mL solution of either dextrose 5% in water (D5W) or 
normal saline and the control group (n=47). Their results 
demonstrated that hospital mortality was estimated to 8.5% (4 
out of 47) in the ascorbic acid treatment group compared with 
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40.4% (19 out of 47) noted in the control group. Natarajan et 
al.,9  divided 24 patients into three groups: 1) Placebo: 5% dex-
trose and water; 2) Low dose ascorbic acid (Lo): 50 mg/kg/24 
hours; and 3) High dose ascorbic acid (Hi): 200 mg/kg/24 
hours. It appeared that cfDNA values were higher and re-
mained elevated for 96 h. mtDNA values were increased in the 
placebo group, whereas they decreased in the treatment 
group. Red cell distribution width (RDW) increased significantly 
only in the placebo group, while the expression of antimicrobi-
al proteins increased significantly only in the treatment group. 
Their findings concluded that ascorbic acid administration 
could improve the effects of sepsis by reducing the levels of 
cfDNA and mtDNA, while causing an increase in endogenous 
antimicrobial proteins and the maintenance of RDW. 
A recent study by Sadaka et al.,10 included 62 patients and 
demonstrated that the combination of ascorbic acid, thiamine 
and hydrocortisone.The exact doses of each medicine .were: . 
ascorbic acid [1.5 g every 6 hours for 4 days], hydrocortisone 
[50 mg every 6 hours for 7 days], and thiamine [200 mg every 
12 hours for 4 days].They concluded that ATS  compared with 
the NO ATS group had longer duration of vassopressors 
(P=o,oo1), lower intensive care unit mortality (P=0,004)   
Shin et al.,11 reported in a study of 1,144 people that early ad-
ministration of vitamin C and thiamine in patients with septic 
shock did not improve survival, whereas administration could 
benefit the patients in more severe conditions, such as hypoal-
buminemia or severe organ failure. In particular, mortality rates 




On the basis of the investigations, it emerged that the majority 
of the studies indicated that ascorbic acid has beneficial prop-
erties in sepsis and septic shock such as lower duration on me-
chanical ventilation, decreased intensive care unit mortality and 
reductions on the SOFA score.  Several studies stress the im-
portance of the combined administration of ascorbic acid and 
other vitamins and trace elements to the patient. 
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Records identified through data-
base searching 




























Additional records identified 
through other sources 
(n = 0  ) 
Records after duplicates removed 
(n =410   ) 
Records screened 
(n =  399 ) 
Records excluded 
(n = 200  ) 
Full-text articles assessed 
for eligibility 
(n =199   ) 
Full-text articles excluded, 
with reasons 
(n =193   ) 
Studies included in quali-
tative synthesis 
(n =  6 ) 
Studies included in quantitative 
synthesis (meta-analysis) 
(n =  6 ) 
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Table 1. Summary table presenting the characteristics of the study 
AYTHOR STUDY DESIGN POPULATION FINDINGS CONCLUSIONS 




44 patients with 
critical disease (24 
with septic shock, 
17 non-septic, 3 
unclassified) 
Nearly 40% of patients with septic 
shock were deficient in vitamin C, 
compared to 25% of non-septic pa-
tients. 
Septic shock patients have signifi-
cantly depleted vitamin C levels 
compared with non-septic patients  
due to the enhanced inflammatory 
response observed in septic shock. 
 






24 patients with 
severe sepsis were 
randomized 1:1:1 to 
receive 
intravenous infu-
sions every six 
hours for four days 
of ascorbic acid: Lo-




Patients treated with ascorbic acid 
experienced immediate reductions in 
SOFA 
while placebo patients showed no 
such reduction. Ascorbic acid signifi-
cantly reduced pro-inflammatory 
biomarkers C-reactive protein and 
procalcitonin. Unlike patients treated 
with placebo, thrombomodulin infu-
sion into patients receiving ascorbic 
acid did not show a significant in-
crease, indicating a weakening of 
vascular endothelial damage. 
Pharmacologic ascorbic acid reple-
tion reduces the extent of multiple 
organ failure and attenuates circu-





study after a 
clinical trial 
94 patients were 
divided into the 
treatment group 
(n=47) and the con-
trol group (n=47) 
Hospital mortality was 
8.5% (4 out of 47) in the treatment 
group compared to 40.4% (19 out of 
47) in the control group. The adjust-
ed mortality forecast in patients 
treated with vitamin 
C was 0.13 
The 
early use of intravenous vitamin C, 
together with 
moderate-dose hydrocortisone and 
thiamine, may prove 
to be effective in preventing pro-
gressive organ 
dysfunction, including acute kidney 
injury, and reducing 
the mortality of patients with se-











ascorbic acid in 
severe sepsis 
24 patients cfDNA values were higher and re-
mained elevated for 96 hours. 
mtDNA values 
increased in the placebo group, but 
decreased in treatment groups with-
out achieving statistical significance. 
RDW increased significantly only in 
the placebo group, while the expres-
sion of antimicrobial proteins in-
creased 
significantly only in treatment groups 
Pharmacologic ascorbic acid reple-
tion 
reduces the extent of multiple or-
gan failure and attenuates mortali-
ty 
by multiple mechanisms involving 
potential reductions in circulating 
cf-DNA and mtDNA levels, augmen-
tation of endogenous 
antimicrobial proteins such as α4D 
and BPI as well as preservation of 
RDW. Infusion of ascorbic acid in 
pharmacological dosages to critical-
ly ill 
patients with sepsis may provide 
adjunctive therapy in the treat-
ment 
of severe sepsis. 
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62 patients The ATS team had a longer VP dura-
tion 
(Corresponding RRT for AKI (26 vs. 
29%), similar days without MV  
(9.6 vs. 42%), and a trend towards 
lower hospital mortality (29 vs. 
45%) compared to NO ATS 
Patients with SS who were treated 
with ascorbic acid, thiamine, 
and hydrocortisone had a reduced 
ICU mortality compared 
with patients with SS with similar 
acuity who were not treated 
with ascorbic acid, thiamine, and 
hydrocortisone. Complications did 
not differ between the groups.  
 





ed with intravenous 
treatment of 
Vitamin C and thi-
amine after shock 
recognition from 
July 
to December 2017 
(n=229) and 915 
patients in the con-
trol group from 
October 2015 to 
June 2017 (n=915 
 
In 28 days (18.3 vs. 17.5%, p=0.76) in 
hospital 
(16.6 vs. 18.3%, r=0.55), mortality 
rates did not differ between treat-
ment and control groups; 
neither did 28-day mortality rates 
(18.5 vs. 17.5%, p=0.84) and in hospi-
tal (16.7 vs. 18.4%, p=0.54) 
after the mapping. In the subgroup 
analysis, treatment was associated 
with lower inpatient mortality 
patients with albumin <3.0 mg/dL 
Intravenous vitamin C and thiamine 
infusion during the initial resuscita-
tion period in patients with septic 
shock was not associated with im-
proved survival. Considering the 
individual variability of patients 
with sepsis, its use could be benefi-
cial in a subgroup of patients, such 
as those with hypoalbuminemia or 
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